B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Latest Information Update: 21 Aug 2024
At a glance
- Drugs CAR-T cell therapies (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mesna (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms 3CAR
- 07 Aug 2023 Planned End Date changed from 28 Feb 2026 to 1 Mar 2027.
- 07 Aug 2023 Planned primary completion date changed from 28 Mar 2025 to 1 Mar 2026.
- 20 Jan 2023 Planned End Date changed from 1 Mar 2027 to 28 Feb 2026.